Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 6.51%
As of Wednesday, July 29, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 6.51%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. COAG
$47.55
0.08
0.17%
July 31, 2026 4:00:00 PM
EST
Volume: 447,285
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 5.06%
As of Tuesday, July 28, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 6.70%
As of Thursday, July 23, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 6.70%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 7.64%
As of Friday, July 17, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 7.64%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 6.81%
As of Wednesday, July 15, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 6.81%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | COAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,220.8 | $252.6 | 55% |
|
| Shares Out (Mil) | 0.9 | 52.3 | 4% |
|
| Institutional Ownership | 98.7% | 92.1% | 81% |
|
| Float (Mil) | 23.7 | 40.2 | 32% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 510 | 455 | 59% |
|
| Price Change (52-week) |
na | 52.9% | na |
|
| Growth | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($71) | ($43) | 13% |
|
| EPS (TTM) | ($75.364) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 15% |
|
| Enterprise Value (Q1) (Mil) | $2,453 | $180 | 52% |
|
| Valuation | COAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | COAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (81.4%) | (49.8%) | 7% |
|
| ROE | 71.8% | (55.5%) | 95% |
|
| Liabilities to Assets | 7.8% | 30.3% | 4% |
|
| F-Score | 1 | 3 | na |
|
Hemab Therapeutics Holdings, Inc. did not pass any screens on 7/31/2026.
